孕前、孕期及产后母亲B族维生素和维生素D状态及孕前和孕期补充的影响:NiPPeR双盲随机对照试验的预设次要分析
NiPPeR双盲随机对照试验纳入1729名计划妊娠女性,随机接受标准维生素补充(对照组859名)或强化维生素补充(干预组870名)。孕前超过90%的参与者至少一种维生素处于边缘或低水平;强化补充组在补充1个月后核黄素、维生素B6、B12和维生素D水平显著高于对照组,且孕期维持较高水平。
要点
- 孕前超过90%的参与者至少一种维生素(叶酸、核黄素、B12或D)处于边缘或低水平。
- 对照组维生素B6和B12浓度随孕期下降,孕28周时较基线低超过1个SDS。
- 强化补充组补充1个月后核黄素、B6、B12、D水平均显著高于对照组,并维持至孕期。
核心结论
- 孕前超过90%的试验参与者至少一种维生素(叶酸、核黄素、维生素B12或维生素D)浓度处于边缘或低水平,许多参与者在孕晚期出现维生素B6缺乏标志物。
- 孕前/孕期补充非处方剂量的维生素可大幅降低维生素缺乏和耗竭标志物的患病率,并在推荐哺乳期维持较高的母亲血浆维生素B12水平。
研究设计与样本
- NiPPeR双盲随机对照试验纳入来自英国、新加坡和新西兰的1729名18至38岁计划妊娠女性,随机接受标准维生素补充(对照组859名)或强化维生素补充(干预组870名),从孕前开始并贯穿孕期。
- 两组共同补充成分包括叶酸、β-胡萝卜素、铁、钙和碘;干预组额外补充核黄素、维生素B6、B12、D(非处方补充剂可用剂量)、肌醇、益生菌和锌。
- 研究主要结局为孕28周口服葡萄糖耐量试验评估的糖耐量;本研究报告的次要结局为孕前和孕期核黄素、维生素B6、维生素B12和维生素D不足的减少。
- 在招募时、孕前开始干预1个月后、孕早期(孕7至11周)、孕晚期(约孕28周)和产后(停止补充6个月后)测量母亲血浆B族维生素、维生素D及不足/缺乏标志物(同型半胱氨酸、羟基犬尿氨酸比值、甲基丙二酸)。
主要发现
- 招募时血浆边缘或低水平的比例分别为:叶酸(<13.6 nmol/L)29.2%,核黄素(<5 nmol/L)7.5%和(≤26.5 nmol/L)82.0%,维生素B12(<221 pmol/L)9.1%,维生素D(<50 nmol/L)48.7%,组间均衡。
- 对照组中核黄素浓度随孕早、晚期下降,25-羟基维生素D在孕早期不变,维生素B6和B12贯穿孕期下降,孕28周时较基线低超过1个SDS。
- 对照组54.2%的参与者在孕晚期出现低维生素B6浓度(吡哆醛5-磷酸<20 nmol/L)。
- 补充1个月后,干预组核黄素较对照组高0.77 SDS(95%CI 0.68至0.87,p<0.0001),维生素B6高1.07 SDS(0.99至1.14,p<0.0001),维生素B12高0.55 SDS(0.46至0.64,p<0.0001),维生素D高0.51 SDS(0.43至0.60,p<0.0001),孕期维持较高水平。
- 孕晚期维生素D不足(<50 nmol/L)的比例干预组低于对照组(35.1% vs 8.5%;p<0.0001);产后6个月干预组血浆维生素B12仍高于对照组(高0.30 SDS,95%CI 0.14至0.46,p=0.0003)。
临床怎么用
- 作者结论指出,孕前/孕期补充非处方剂量的维生素可大幅降低维生素缺乏和耗竭标志物的患病率,并在推荐哺乳期维持较高的母亲血浆维生素B12水平。
局限性
- 主要局限性在于研究在高资源环境中进行,尤其缺乏非洲和美洲印第安女性,限制了向全球人群的推广。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Maternal vitamin status preconception and during pregnancy has important consequences for pregnancy outcome and offspring development. Changes in vitamin status from preconception through early and late pregnancy and postpartum have been inferred from cross-sectional data, but longitudinal data on vitamin status from preconception throughout pregnancy and postdelivery are sparse. As such, the influence of vitamin supplementation on vitamin status during pregnancy remains uncertain. This study presents one prespecified outcome from the randomized controlled NiPPeR trial, aiming to identify longitudinal patterns of maternal vitamin status from preconception, through early and late pregnancy, to 6 months postdelivery, and determine the influence of vitamin supplementation. METHODS AND FINDINGS: In the NiPPeR trial, 1,729 women (from the United Kingdom, Singapore, and New Zealand) aged 18 to 38 years and planning conception were randomized to receive a standard vitamin supplement (control; n = 859) or an enhanced vitamin supplement (intervention; n = 870) starting in preconception and continued throughout pregnancy, with blinding of participants and research staff. Supplement components common to both treatment groups included folic acid, β-carotene, iron, calcium, and iodine; components additionally included in the intervention group were riboflavin, vitamins B6, B12, and D (in amounts available in over-the-counter supplements), myo-inositol, probiotics, and zinc. The primary outcome of the study was glucose tolerance at 28 weeks' gestation, measured by oral glucose tolerance test. The secondary outcome reported in this study was the reduction in maternal micronutrient insufficiency in riboflavin, vitamin B6, vitamin B12, and vitamin D, before and during pregnancy. We measured maternal plasma concentrations of B-vitamins, vitamin D, and markers of insufficiency/deficiency (homocysteine, hydroxykynurenine-ratio, methylmalonic acid) at recruitment, 1 month after commencing intervention preconception, in early pregnancy (7 to 11 weeks' gestation) and late pregnancy (around 28 weeks' gestation), and postdelivery (6 months after supplement discontinuation). We derived standard deviation scores (SDS) to characterize longitudinal changes among participants in the control group and measured differences between the 2 groups. At recruitment, the proportion of patients with marginal or low plasma status was 29.2% for folate (<13.6 nmol/L), 7.5% and 82.0% for riboflavin (<5 nmol/L and ≤26.5 nmol/L, respectively), 9.1% for vitamin B12 (<221 pmol/L), and 48.7% for vitamin D (<50 nmol/L); these proportions were balanced between the groups. Over 90% of all participants had low or marginal status for one or more of these vitamins at recruitment. Among participants in the control group, plasma concentrations of riboflavin declined through early and late pregnancy, whereas concentrations of 25-hydroxyvitamin D were unchanged in early pregnancy, and concentrations of vitamin B6 and B12 declined throughout pregnancy, becoming >1 SDS lower than baseline by 28 weeks gestation. In the control group, 54.2% of participants developed low late-pregnancy vitamin B6 concentrations (pyridoxal 5-phosphate <20 nmol/L). After 1 month of supplementation, plasma concentrations of supplement components were substantially higher among participants in the intervention group than those in the control group: riboflavin by 0.77 SDS (95% CI 0.68 to 0.87, p < 0.0001), vitamin B6 by 1.07 SDS (0.99 to 1.14, p < 0.0001), vitamin B12 by 0.55 SDS (0.46 to 0.64, p < 0.0001), and vitamin D by 0.51 SDS (0.43 to 0.60, p < 0.0001), with higher levels in the intervention group maintained during pregnancy. Markers of vitamin insufficiency/deficiency were reduced in the intervention group, and the proportion of participants with vitamin D insufficiency (<50 nmol/L) during late pregnancy was lower in the intervention group (35.1% versus 8.5%; p < 0.0001). Plasma vitamin B12 remained higher in the intervention group than in the control group 6 months postdelivery (by 0.30 SDS (0.14, 0.46), p = 0.0003). The main limitation is that generalizability to the global population is limited by the high-resource settings and the lack of African and Amerindian women in particular. CONCLUSIONS: Over 90% of the trial participants had marginal or low concentrations of one or more of folate, riboflavin, vitamin B12, or vitamin D during preconception, and many developed markers of vitamin B6 deficiency in late pregnancy. Preconception/pregnancy supplementation in amounts available in over-the-counter supplements substantially reduces the prevalence of vitamin deficiency and depletion markers before and during pregnancy, with higher maternal plasma vitamin B12 maintained during the recommended lactational period. TRIAL REGISTRATION: ClinicalTrials.gov NCT02509988; U1111-1171-8056.
引用
- Godfrey KM, Titcombe P, El-Heis S, et al. Maternal B-vitamin and vitamin D status before, during, and after pregnancy and the influence of supplementation preconception and during pregnancy: Prespecified secondary analysis of the NiPPeR double-blind randomized controlled trial. PLoS Med. 2023. PMID: 38051700. doi:10.1371/journal.pmed.1004260
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。